News

Deciphera president and CEO Dr Michael Taylor said: “We are extremely pleased with the recent progress made on our rebastinib program, including today’s announcement that we have initiated

The merger of Bristol-Myers Squibb and Celgene is expected to result in a specialty biopharma company that will strive to develop high-value innovative medicines to meet the needs

The EGFR previously treated cohort is part of the ZENITH20 trial – an open-label, multi-center, global Phase 2 trial evaluating NSCLC patients with EGFR or HER2 exon 20

The settlement with Mylan is the third patent infringement settlement the companies have reached with respect to LINZESS. Pursuant to the terms of the settlement, Ironwood and Allergan

ITOCHU is the first lead investor in Promethera’s new investment round, which is expected to be completed in the first quarter of this year. The US pharma firm is

The expanded indication for Sprycel is in combination with chemotherapy. It was granted by the regulator following priority review based on the findings of the phase 2 study,

Nuvo’s president and CEO Jesse Ledger said: “The close of this transaction positions Nuvo as one of the premier specialty pharmaceutical companies in Canada. “Nuvo is now truly

Antengene has secured the money under series B financing round led by Boyu Capital and FountainVest. The participants include new investors such as Celgene, WuXi Corporate Venture Fund

Andexxa received both U.S. Orphan Drug and FDA Breakthrough Therapy designations and was initially approved on May 3, 2018 under the FDA’s Accelerated Approval pathway. It is the